G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists. 2021

Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
Department of Molecular Medicine, Scripps Research, Jupiter, FL 33458.

The ability of a ligand to preferentially promote engagement of one signaling pathway over another downstream of GPCR activation has been referred to as signaling bias, functional selectivity, and biased agonism. The presentation of ligand bias reflects selectivity between active states of the receptor, which may result in the display of preferential engagement with one signaling pathway over another. In this study, we provide evidence that the G protein-biased mu opioid receptor (MOR) agonists SR-17018 and SR-14968 stabilize the MOR in a wash-resistant yet antagonist-reversible G protein-signaling state. Furthermore, we demonstrate that these structurally related biased agonists are noncompetitive for radiolabeled MOR antagonist binding, and while they stimulate G protein signaling in mouse brains, partial agonists of this class do not compete with full agonist activation. Importantly, opioid antagonists can readily reverse their effects in vivo. Given that chronic treatment with SR-17018 does not lead to tolerance in several mouse pain models, this feature may be desirable for the development of long-lasting opioid analgesics that remain sensitive to antagonist reversal of respiratory suppression.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D010880 Piperidines A family of hexahydropyridines.
D000071560 beta-Arrestin 2 A beta-arrestin that functions similarly to BETA-ARRESTIN 1 in regulating signaling by G-PROTEIN-COUPLED RECEPTORS. It is expressed at high levels in the central nervous system where it may regulate signaling by SYNAPTIC RECEPTORS. ARRB2 Protein,Arrestin, beta 2,Arrestin-3,Arrestin 3,beta 2 Arrestin,beta Arrestin 2
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
December 2020, Biological psychiatry,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
August 2021, Behavioural pharmacology,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
November 2018, Trends in pharmacological sciences,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
March 2006, British journal of pharmacology,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
January 1999, British journal of pharmacology,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
June 2022, Angewandte Chemie (International ed. in English),
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
July 2000, Brain research bulletin,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
October 2015, Journal of neurochemistry,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
January 2001, Brain research bulletin,
Edward L Stahl, and Cullen L Schmid, and Agnes Acevedo-Canabal, and Cai Read, and Travis W Grim, and Nicole M Kennedy, and Thomas D Bannister, and Laura M Bohn
December 2022, ChemMedChem,
Copied contents to your clipboard!